Marcela Maus, MD, PhD, director of the Cellular Immunotherapy Program and the Paula J. O'Keeffe Endowed Chair of the Mass General Cancer Center, is senior author and Stefanie Bailey, PhD, Hana Takei, and Giulia Escobar, PhD of the Krantz Family Center for Cancer Research at Massachusetts General Hospital are co-lead authors of a paper published in Science Translational Medicine, “IFN-g-resistant CD28 CAR-T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor models.”

(WASHINGTON, June 13, 2025) – Women with breast cancer who were also carriers of the BRCA1 or BRCA2 mutation and received textured breast implants as part of their reconstructive surgery after mastectomy were 16 times more likely to develop breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare T-cell lymphoma, compared with similar women without these genetic mutations, according to a study published today in Blood Advances.

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.

Major depressive disorder (MDD), a mental health condition characterized by persistent low mood and cognitive impairments, is associated with a poor quality of life. A new systematic review published in Neuroprotection reveals the critical mechanistic pathways involving astrocytes that drive neuroinflammation in MDD. These astrocyte-mediated pathways can be targeted by novel pharmacological agents, leading to the development of innovative therapeutic strategies to treat MDD and other psychiatric conditions.